BAVA:CPH
Bavarian Nordic A/S
DKKÂ 240.40
arrow_upward
+1.52%(+3.60) 1D
Oct 12, 2:33:37 PM GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKKÂ 233.40
High
DKKÂ 241.20
Low
DKKÂ 231.20
Mkt. cap
18.77B
Avg. vol.
172.92K
Volume
308.14K
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.27M
No. of employees
2K
Open
DKKÂ 233.40
High
DKKÂ 241.20
Low
DKKÂ 231.20
Mkt. cap
18.77B
Avg. vol.
172.92K
Volume
308.14K
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.27M
No. of employees
2K
News stories
From web sources and news partners
TradingView
·
47 minutes ago
Stocks Are Near Records. Can Q3 Earnings Boost the Rally?
Finbold
·
25 minutes ago
This Grok portfolio just destroyed the S&P 500
Investing.com
·
57 minutes ago
Dow Jones, Nasdaq, S&P 500 preview: Markets brace for CPI, Q3 earnings kick-off
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com